Is MDG1.DE stock a buy after the drop on 18 Mar 2026?

MDG1.DE stock may offer a tactical oversold bounce, but fundamentals remain weak. Use small size and tight stops. Consider short-term scalp targets like €0.20 and reassess after any recovery.

What is Meyka AI's forecast for MDG1.DE stock?

Meyka AI's forecast model projects **€0.25** for MDG1.DE stock versus the current **€0.1335**, implying about **87.31%** upside. Forecasts are model-based projections and not guarantees.

What technical signs confirm an oversold bounce in MDG1.DE stock?

Look for declining volume on down ticks, rising intraday lows, and a rebound with above-average volume. For MDG1.DE stock, watch a clear higher-low and volume confirmation before adding exposure.

How large is Medigene AG and what are the financial risks?

Medigene AG has a market cap of about **€1,967,470.00**, EPS **-1.21**, and cash per share about **€1.36**. Risks include dilution, trial setbacks, and thin liquidity that can amplify moves in MDG1.DE stock.

DE Stocks

MDG1.DE Medigene AG (XETRA) down 27% 18 Mar 2026: Oversold bounce trade to watch

ByDanny Kontos March 19, 2026

MDG1.DE stock dropped to €0.13 (last trade €0.1335) on XETRA at Market Close on 18 Mar 2026, a -27.64% intraday move that leaves the name deeply oversold. Volume surged to 189,470 shares versus an average of 43,152, a signal of heavy selling followed by possible short-term relief. Traders looking for an oversold bounce should weigh the steep discount to the 50-day average (€1.41) against weak earnings and small market cap, and monitor flows into the stock carefully.